… and may underlie the adverse outcomes predicted by CD56 antigen. The limitation of this
study … In conclusion, CD200 + and CD56 + expression in AML at diagnosis are poor prognostic …

… , and three others were associated with good prognosis: CD19, … aberrant expression of
CD56 as a poor prognostic marker with … related to positive or negative and high or low antigen …

… in patients of acute myeloid leukaemia could be indicative of poor prognosis as it was also
associated with the adverse … CD56 antigen [6] is a NK cell marker, which expressed in several …

… associated with acute myeloid leukemia (AML) survival outcomes. CD56 is related to poor
prognosis when expressed … T-cell antigens were not coexpressed with CD56 in AML patients […

… that CD56 positive is associated with poor prognosis of patients with intermediate-risk
acute myeloid … Nevertheless, high expression of CD56 antigen is often associated with poor …

… the expression of surface antigen CD56 and the prognosis of de novo none-M3 AML patients
… that high levels of CD56 expression are a factor for poor prognosis in de novo non-M3 AML …

… within CD56-positive leukemias, poor prognosis is limited to a subset of … expression of the
CD56 antigen and is associated with extremely poor outcomes (16% 3-year event-free survival …

… profiles or other types of antigen expression combinations does somewhat restrict the scope
… As an example co-expression of CD56 and CD7 has been associated with a poor prognosis …

… a poor prognostic biomarker. Identification of CD200 + and CD56 + expression at diagnosis
… in patients who express CD56 antigen on the membrane of the leukemic blasts [Citation33]. …

… CD56 antigen expression was analyzed retrospectively using the bone marrow samples …
on specific monoclonal antibodies against CD56 and CD33 antigen. Cytogenetic analysis of …